This product is a non-peptide endothelin receptor antagonist, which can antagonize endothelin-induced vasoconstriction, blood pressure increase and vascular smooth muscle cell proliferation, reduce vascular endothelial damage; increase NO synthesis, relax vascular smooth muscle; inhibit platelet aggregation, anti-coagulation, and improve blood rheology characteristics. This product can also inhibit cholesterol synthesis, lower blood lipids, scavenge free radicals, prevent lipid peroxidation damage; affect complement, enhance immune function, and have certain analgesic and antispasmodic effects.

Intraperitoneal injection of the drug into mice with cholestatic jaundice induced by 1-naphthyl isothiocyanate can reduce serum aspartate aminotransferase, alanine aminotransferase and serum conjugated bilirubin levels, and alleviate liver cell damage in the model animals.

It has certain anti-inflammatory, liver cell membrane protection and liver function improvement effects. It can reduce the increase of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) caused by carbon tetrachloride, thioacetamide and D-aminogalactic acid, significantly reduce the damage of D-aminogalactic acid to the liver and improve the chronic damage of immune factors to the liver.

Extract from the above information